NasdaqCM:CELCBiotechs
Does Celcuity’s (CELC) Low‑Coupon Convertibles Hint at Strategic Caution or Commercial Ambition?
In early June 2026, Celcuity Inc. priced an upsized underwritten offering of US$500,000,000 in 0.250% convertible senior notes due 2032, planning to repay its Oxford Finance loan and fund clinical, commercialization and general corporate needs, including potential acquisitions.
The detailed Phase 3 VIKTORIA-1 results for gedatolisib in PIK3CA-mutant advanced breast cancer, including efficacy, safety and a planned supplemental FDA filing, now sit alongside this new convertible debt as...